RxDoctor Payments Data

William Roman Aqueron, MD

Urology · Mayaguez, PRNPI 1134123904

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,601 of the $4,101 with a category attached, or 63.4%. 13 manufacturers reported payments, led by Merck at 38.8% of the total. Reporting peaked in 2023 at $1,971 and has fallen 92.3% since, to $152 in 2025.

$4,101in general payments, 2019–2025

Across 34 payments — averaging $120.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$2K
  • Boston Scientific$709
  • Johnson & Johnson$511
  • E.r. Squibb & Sons, L.L.C.$225
  • Neotract Inc.$217
  • Medtronic$179
  • plus $670 from 7 others

What the payments were for

  • Speaking & faculty fees$1,50037%
  • Food & beverage$2,60163%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,101 in reported general payments places this provider in the 70th percentile of 122 urology providers in Puerto Rico.

See all urology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$2,984
Medicare patients
30
Services billed
32

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron18$10,602
PremarinEstrogens, Conjugated19$8,557
Finasteride366$6,791
Tamsulosin Hcl408$5,917
NitrofurantoinNitrofurantoin Macrocrystal40$1,288
Tolterodine Tartrate11$856
Alfuzosin Hcl ErAlfuzosin Hcl36$785
Bicalutamide20$731
Oxybutynin Chloride ErOxybutynin Chloride21$580
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim136$334
Tramadol Hcl-AcetaminophenTramadol Hcl/Acetaminophen12$164
Levofloxacin39$141
GlydoLidocaine Hcl17$122
CeftriaxoneCeftriaxone Sodium22$103
Gentamicin Sulfate14$75

Paid to pharmacies, not to this prescriber.

Other urology in Mayaguez

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →